Nicholas La Thangue, Chief Scientific Officer
Nick is a founder of Argonaut Therapeutics and Professor of Cancer Biology at the University of Oxford. He is a Fellow of the Royal Society of Edinburgh, a Member of the European Molecular Biology Organisation (EMBO), a Fellow of the Academy of Medical Sciences, a Fellow of the Lister Institute and Professorial Fellow at Linacre College Oxford. Nick has founded several companies, including Prolifix, Celleron Therapeutics and Oxford Cancer Biomarkers, and has extensive experience derived from the biotechnology and pharmaceutical sectors.
Stefan Knapp, Chief Technical Officer
Stefan did his PhD in protein crystallography at the Karolinska Institute in Stockholm and continued his career in the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He was a founding scientist at the Structural Genomics Consortium at Oxford University where he was Professor of Structural Biology and Director for Chemical Biology at the Target Discovery Institute. Currently, he is Professor of Pharmaceutical Chemistry at Frankfurt University. His research interests are the rational design of selective inhibitors that target the epigenetic code.